The Role of Cardiovascular Magnetic Resonance Imaging in the Evaluation of Hypertrophic Cardiomyopathy

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2022 Feb 25

PMID 35204405

Authors

Sanjay Sivalokanathan

Affiliations

Soon will be listed here.

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, affecting 1 out of 500 adults globally. It is a widely heterogeneous disorder characterized by a range of phenotypic expressions, and is most often identified by non-invasive imaging that includes echocardiography and cardiovascular magnetic resonance imaging (CMR). Within the last two decades, cardiac magnetic resonance imaging (MRI) has emerged as the defining tool for the characterization and prognostication of cardiomyopathies. With a higher image quality, spatial resolution, and the identification of morphological variants of HCM, CMR has become the gold standard imaging modality in the assessment of HCM. Moreover, it has been crucial in its management, as well as adding prognostic information that clinical history nor other imaging modalities may not provide. This literature review addresses the role and current applications of CMR, its capacity in evaluating HCM, and its limitations.

Citing Articles

Advances in Multi-Modality Imaging in Hypertrophic Cardiomyopathy.

Goldie F, Lee M, Coats C, Nordin S J Clin Med. 2024; 13(3).

PMID: 38337535 PMC: 10856479. DOI: 10.3390/jcm13030842.

Impaired cardiac pump function assessment with normalized cardiac power using cardiac magnetic resonance in patients with hypertrophic cardiomyopathy.

Li Q, Gao X, Zhou Z, Zhang H, Li W, Gao Y Quant Imaging Med Surg. 2023; 13(7):4103-4116.

PMID: 37456301 PMC: 10347308. DOI: 10.21037/qims-22-1119.

Cardiac Multimodality Imaging in Hypertrophic Cardiomyopathy: What to Look for and When to Image.

Wengrofsky P, Akivis Y, Bukharovich I Curr Cardiol Rev. 2023; 19(5):1-18.

PMID: 36927425 PMC: 10518881. DOI: 10.2174/1573403X19666230316103117.

Papillary and Trabecular Muscles Have Substantial Impact on Quantification of Left Ventricle in Patients with Hypertrophic Obstructive Cardiomyopathy.

Yang C, Xu H, Qiao S, Jia R, Jin Z, Yuan J Diagnostics (Basel). 2022; 12(8).

PMID: 36010378 PMC: 9407152. DOI: 10.3390/diagnostics12082029.

References

Varnava A, Elliott P, Sharma S, McKenna W, Davies M . Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000; 84(5):476-82. PMC: 1729476. DOI: 10.1136/heart.84.5.476. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Gastl M, Lachmann V, Christidi A, Janzarik N, Veulemans V, Haberkorn S . Cardiac magnetic resonance T2 mapping and feature tracking in athlete's heart and HCM. Eur Radiol. 2020; 31(5):2768-2777. PMC: 8043946. DOI: 10.1007/s00330-020-07289-4. View

Petersen S, Jerosch-Herold M, Hudsmith L, Robson M, Francis J, Doll H . Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation. 2007; 115(18):2418-25. DOI: 10.1161/CIRCULATIONAHA.106.657023. View

Maron M, Olivotto I, Maron B, Prasad S, Cecchi F, Udelson J . The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009; 54(9):866-75. DOI: 10.1016/j.jacc.2009.04.072. View

Nayak K, Nielsen J, Bernstein M, Markl M, Gatehouse P, Botnar R . Cardiovascular magnetic resonance phase contrast imaging. J Cardiovasc Magn Reson. 2015; 17:71. PMC: 4529988. DOI: 10.1186/s12968-015-0172-7. View

Olivotto I, Girolami F, Sciagra R, Ackerman M, Sotgia B, Bos J . Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol. 2011; 58(8):839-48. DOI: 10.1016/j.jacc.2011.05.018. View

Srichai M, Lim R, Wong S, Lee V . Cardiovascular applications of phase-contrast MRI. AJR Am J Roentgenol. 2009; 192(3):662-75. DOI: 10.2214/AJR.07.3744. View

Messroghli D, Moon J, Ferreira V, Grosse-Wortmann L, He T, Kellman P . Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular.... J Cardiovasc Magn Reson. 2017; 19(1):75. PMC: 5633041. DOI: 10.1186/s12968-017-0389-8. View

10.

Ariga R, Tunnicliffe E, Manohar S, Mahmod M, Raman B, Piechnik S . Identification of Myocardial Disarray in Patients With Hypertrophic Cardiomyopathy and Ventricular Arrhythmias. J Am Coll Cardiol. 2019; 73(20):2493-2502. PMC: 6548973. DOI: 10.1016/j.jacc.2019.02.065. View

11.

Brock R . Functional obstruction of the left ventricle; acquired aortic subvalvar stenosis. Guys Hosp Rep. 1957; 106(4):221-38. View

12.

OHanlon R, Grasso A, Roughton M, Moon J, Clark S, Wage R . Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010; 56(11):867-74. DOI: 10.1016/j.jacc.2010.05.010. View

13.

Bogaert J, Olivotto I . MR Imaging in Hypertrophic Cardiomyopathy: From Magnet to Bedside. Radiology. 2014; 273(2):329-48. DOI: 10.1148/radiol.14131626. View

14.

van Ooij P, Allen B, Contaldi C, Garcia J, Collins J, Carr J . 4D flow MRI and T1 -Mapping: Assessment of altered cardiac hemodynamics and extracellular volume fraction in hypertrophic cardiomyopathy. J Magn Reson Imaging. 2015; 43(1):107-14. PMC: 4850842. DOI: 10.1002/jmri.24962. View

15.

Rudolph A, Abdel-Aty H, Bohl S, Boye P, Zagrosek A, Dietz R . Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol. 2009; 53(3):284-91. DOI: 10.1016/j.jacc.2008.08.064. View

16.

Wang Z, Ohliger M, Larson P, Gordon J, Bok R, Slater J . Hyperpolarized C MRI: State of the Art and Future Directions. Radiology. 2019; 291(2):273-284. PMC: 6490043. DOI: 10.1148/radiol.2019182391. View

17.

Brenes J, Doltra A, Prat S . Cardiac magnetic resonance imaging in the evaluation of patients with hypertrophic cardiomyopathy. Glob Cardiol Sci Pract. 2018; 2018(3):22. PMC: 6209443. DOI: 10.21542/gcsp.2018.22. View

18.

Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu C . T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study. Circ Cardiovasc Imaging. 2015; 8(12). DOI: 10.1161/CIRCIMAGING.115.003285. View

19.

Marstrand P, Han L, Day S, Olivotto I, Ashley E, Michels M . Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. Circulation. 2020; 141(17):1371-1383. PMC: 7182243. DOI: 10.1161/CIRCULATIONAHA.119.044366. View

20.

McGill L, Ismail T, Nielles-Vallespin S, Ferreira P, Scott A, Roughton M . Reproducibility of in-vivo diffusion tensor cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012; 14:86. PMC: 3551746. DOI: 10.1186/1532-429X-14-86. View